Patents by Inventor Reinhard Jork

Reinhard Jork has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazotriazines for use as phosphodiesterase inhibitors
    Patent number: 6936609
    Abstract: The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: August 30, 2005
    Assignee: Bayer HealthCare AG
    Inventors: Jens-Kerim Ergüden, Marcus Bauser, Nils Burkhardt, Dietmar Flubacher, Arno Friedl, Irene Gerlach, Volker Hinz, Reinhard Jork, Paul Naab, Maria Theresia Niewöhner, Thorsten Oliver Repp, Karl-Heinz Schlemmer, Jürgen Stoltefuss, David Brückner, Martin Hendrix, Dagmar Schauss, Adrian Tersteegen, Ulrich Niewöhner
  • Imidazotriazines for use as phosphodiesterase inhibitors
    Publication number: 20040249148
    Abstract: The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.
    Type: Application
    Filed: June 25, 2004
    Publication date: December 9, 2004
    Inventors: Jens-Kerim Erguden, Marcus Bauser, Nils Burkhardt, Dietmar Flubacher, Arno Friedl, Irene Gerlach, Volker Hinz, Reinhard Jork, Paul Naab, Ulrich Niewohner, Maria Theresia Niewohner, Thorsten Oliver Repp, Karl-Heinz Schlemmer, Jurgen Stoltefuss, David Bruckner, Martin Hendrix, Dagmar Schauss, Adrian Tersteegen
  • Arylsulphonamides and analogues
    Patent number: 6727279
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: April 27, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
    Patent number: 6573278
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: June 3, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horváth, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Novel arylsulphonamides and analogues
    Publication number: 20030073727
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Application
    Filed: August 21, 2002
    Publication date: April 17, 2003
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jorg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvath, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6525087
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: February 25, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Use of chromans
    Publication number: 20020177616
    Abstract: The invention relates to the use of 2-[4-({[(2R)-8-isopropoxy-chroman-2-yl]-methyl}amino)butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, its physiologically acceptable salts, hydrates and/or solvates, in particular its hydrochloride, for the production of a medicament for the prophylaxis and/or treatment of Parkinson's disease.
    Type: Application
    Filed: January 9, 2002
    Publication date: November 28, 2002
    Inventors: Thomas Fahrig, Irene Gerlach, Ervin Horvath, Reinhard Jork, Frank Mauler
  • Aryl sulphonamides and analogues
    Patent number: 6469054
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: October 22, 2002
    Assignee: Bayer Aktiengesellshaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Arylsulfonamides and analogues
    Publication number: 20020072529
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: June 11, 2001
    Publication date: June 13, 2002
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jorg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horvath, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
    Patent number: 6331561
    Abstract: The invention relates to the use of substituted aminomethyl-chromans for the treatment of neuronal degeneration and for the promotion of neuronal regeneration in cerebral injuries and chronic disorders of the nervous system.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: December 18, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Thomas Fahrig, Irene Gerlach, Ervin Horváth, Reinhard Jork
  • Use of known agonists of the central cannabinoid receptor CB1
    Publication number: 20010034344
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: May 29, 2001
    Publication date: October 25, 2001
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6284788
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: September 4, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
    Publication number: 20010018530
    Abstract: The invention relates to the use of substituted aminomethyl-chromans for the treatment of neuronal degeneration and for the promotion of neuronal regeneration in cerebral injuries and chronic disorders of the nervous system.
    Type: Application
    Filed: March 9, 2001
    Publication date: August 30, 2001
    Inventors: Thomas Fahrig, Irene Gerlach, Ervin Horvath, Reinhard Jork
  • Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
    Patent number: 6262112
    Abstract: The present invention relates to new aryl ether sulphonamides and analogs, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: July 17, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horváth, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
    Patent number: 6235774
    Abstract: The invention relates to the use of substituted aminomethyl-chromans for the treatment of neuronal degeneration and for the promotion of neuronal regeneration in cerebral injuries and chronic disorders of the nervous system.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: May 22, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Thomas Fahrig, Irene Gerlach, Ervin Horváth, Reinhard Jork
  • Benzisothiazolyl-substituted aminomethylchromans
    Patent number: 5942529
    Abstract: The benzisothiazolyl-substituted aminomethylchromans are prepared either by substituting the corresponding unsubstituted aminomethylchromans on the amine nitrogen or reacting the corresponding benzisothiazolylalkylamines with appropriate activated methylchromans or reacting the amine nitrogen of aminomethylchroman first with an appropriately substituted alkine and then hydrogenating. The benzisothiazolyl-substituted aminomethylchromans can be used as active compounds in medicaments, in particular in medicaments for the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: June 13, 1996
    Date of Patent: August 24, 1999
    Assignee: Bayer Aktiengesellschaft
    Inventors: Rudolf Schohe-Loop, Hans-Georg Heine, Peter-Rudolf Seidel, Wolfgang Kanhai, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Thomas Glaser, Reinhard Jork